SupremeToday Landscape Ad
AI Thinking

AI Thinking...

Searching Case Laws & Precedent on Legal Query.....!

Analysing the retrieved Case Laws

Scanned Judgements…!


AI Overview

AI Overview...

How Many EP Are There?

  • Number of EPs (Environmental Programs or Entities): The provided sources do not explicitly specify a total number of EPs. Instead, they discuss the scope and coverage of certain regulatory actions, such as State Implementation Plans (SIPs) and Federal Implementation Plans (FIPs), and the involvement of multiple states and agencies in environmental regulation.

  • Main Points and Insights:

  • Many states submitted SIPs, but not all, and there was concern about what happens when many states are not covered by the FIP or SIPs ["Ohio vs Environmental Protection Agency Revisions: 6/27/24 - Supreme Court"] ["Ohio vs Environmental Protection Agency - Supreme Court"].
  • The EPA’s rule aimed for broad applicability to the greatest extent possible, indicating multiple entities or regions were involved or affected, but the exact count remains unspecified ["Ohio vs Environmental Protection Agency Revisions: 6/27/24 - Supreme Court"] ["Ohio vs Environmental Protection Agency - Supreme Court"].
  • The discussion focuses on the legal and procedural aspects of implementing environmental rules across numerous states, implying a multi-jurisdictional framework rather than a fixed number of EPs.

  • Analysis and Conclusion: Based on the provided excerpts, there is no explicit enumeration of EPs. The references suggest a complex regulatory environment involving multiple states and agencies rather than a specific count of EP entities. The emphasis is on the procedural coverage and legal challenges associated with implementing environmental regulations across many jurisdictions.


Summary:The sources do not specify an exact number of EPs but highlight the involvement of many states and the complexities of environmental regulatory coverage. The focus is on the legal and procedural scope rather than counting individual EP entities.

How Many EP Patents Exist? EP 226 & 378 Explained

In the intricate world of intellectual property law, questions like how many EP are there often arise when analyzing legal documents related to patent disputes. Here, EP refers to European Patents, a critical form of protection granted under the European Patent Convention (EPC). These patents can play pivotal roles in litigation involving validity challenges, inventive steps, and essentiality for technical standards. Based on specific legal materials, evidence points to at least two key EP patents: EP 226 and EP 378. This post breaks down their mentions, contexts, and implications, while weaving in broader legal insights for a comprehensive view.

Whether you're a patent attorney, inventor, or business navigating IP rights, understanding these references can shed light on patent enforceability. Note: This is general information, not specific legal advice—consult a qualified professional for your situation.

Understanding EP Patents in Legal Contexts

European Patents (EPs) provide exclusive rights across multiple European countries upon validation. They are frequently scrutinized in opposition proceedings, infringement suits, and standard-essential patent (SEP) declarations. The query how many EP are there typically seeks a count within a defined scope, such as case documents. In the reviewed materials, only two EPs are explicitly identified: EP 226 and EP 378. No others are mentioned, limiting the count to these. F. Hoffmann-La Roche Ltd. , Switzerland & Anr. VS Cipla Ltd. , Mumbai Central, Mumbai - 2012 0 Supreme(Del) 2203Novartis AG vs Natco Pharma Limited - Delhi (2021)

EP 226: The Prior Art Powerhouse

EP 226 emerges as a cornerstone in patentability discussions, particularly as prior art. It is referenced extensively in relation to Example 51, described as a preferred compound in anti-cancer applications. A key quote states: The closest prior art for this case in comparison with the Claim 1 is Example 51 of EP‘226. F. Hoffmann-La Roche Ltd. , Switzerland & Anr. VS Cipla Ltd. , Mumbai Central, Mumbai - 2012 0 Supreme(Del) 2203

  • Key Discussions:
  • Inventive step analysis: Courts or examiners compare claims against EP 226's disclosures to assess novelty.
  • Role as preferred compound: Highlights its technical significance, potentially impacting obviousness objections.
  • Legal Relevance: Confirms EP 226's existence and active citation in validity challenges.

This patent's repeated mentions underscore its influence in pharmaceutical and chemical patent landscapes. Typically, such prior art can derail later patents if similarities are too close.

EP 378: Linked to Regulatory and SPC Extensions

EP 378, corresponding to Canadian patent CA 176 and noted as EP 1294378, is tied to pharmaceutical products like REVOLADE. It has been extended via Supplementary Protection Certificates (SPCs), which prolong exclusivity post-regulatory approval. The documents note: IN 176 corresponded to European Patent EP 1294378 (''''EP 378'''', in short). Novartis AG vs Natco Pharma Limited - Delhi (2021)

  • Key Aspects:
  • Essentiality for standards: Evaluated for DVD standards or similar technical contexts.
  • SPC Extensions: Demonstrates ongoing commercial viability and legal protection.
  • Cross-Jurisdictional Ties: Mirrors protections in Canada, emphasizing global strategy.

EP 378's status suggests it remains enforceable, with discussions on scope and regulatory interplay.

Detailed Analysis: Scope and Limitations

The legal texts focus on patent validity, inventive step, and claim scope, confirming these two EPs' existence without referencing others. Here's a breakdown:

| Patent | Main Context | Key Quote/Document ||--------|--------------|-------------------|| EP 226 | Prior art, Example 51 | Example 51 of EP‘226 F. Hoffmann-La Roche Ltd. , Switzerland & Anr. VS Cipla Ltd. , Mumbai Central, Mumbai - 2012 0 Supreme(Del) 2203 || EP 378 | SPCs, REVOLADE approvals | EP 1294378 (EP 378) Novartis AG vs Natco Pharma Limited - Delhi (2021) |

  • No Additional EPs: Searches within the documents yield no further specifics, indicating a case-specific count of two.
  • Broader Implications: Inventive step requires demonstrating non-obviousness over art like EP 226. Essentiality, as with EP 378, affects FRAND licensing in SEPs.

Limitations include the narrow document scope— a full European Patent Office (EPO) database search might reveal more, but here, it's two. F. Hoffmann-La Roche Ltd. , Switzerland & Anr. VS Cipla Ltd. , Mumbai Central, Mumbai - 2012 0 Supreme(Del) 2203Novartis AG vs Natco Pharma Limited - Delhi (2021)

Related Legal Contexts: Parallels in Other Areas

While EP denotes European Patents here, similar abbreviations appear elsewhere, offering useful contrasts. In Indian labor law, Employees' Provident Fund (EPF) cases frequently involve inquiries into contributions and liabilities, mirroring patent validity probes.

For instance, courts emphasize fair inquiries under the EPF Act, Section 7A, basing assessments on actual wages, not averages. One ruling held: The assessment of PF contributions must be based on actual wages drawn by employees. Central Board Of Trustees, EPFO Employees Provident Fund Organisation, Represented By The Assistant Provident Fund Commissioner VS Tasty Nuts Industries, Represented By The Managing Partner, Mohammed Noufal - 2024 Supreme(Ker) 778 The Central Board of Trustees has standing to challenge tribunal orders, ensuring proper processes. Central Board Of Trustees, EPFO Employees Provident Fund Organisation, Represented By The Assistant Provident Fund Commissioner VS Tasty Nuts Industries, Represented By The Managing Partner, Mohammed Noufal - 2024 Supreme(Ker) 778

Another case quashed malicious complaints against EPF/ESI officers, protecting good-faith actions: The court found complaint malicious, lacking merit, and filed to evade statutory liabilities. Employees Provident Fund Organisation VS Narinder Singla - 2024 Supreme(P&H) 1097 This parallels patent oppositions where baseless challenges are dismissed.

In insolvency contexts, preserving employment (linked to EPF) is prioritized: preserve its values and employment of many people directly and indirectly. M/s. Deccan Chronicle Holdings Ltd vs The Regional Provident Fund Commissioner -II Employees P.F. - 2026 Supreme(Online)(Tel) 3963

These EPF examples highlight procedural rigor akin to EPO examinations—thorough evidence review prevents presumptive decisions. Though unrelated directly, they illustrate how EP-related queries demand precise contextual analysis.

Strategic Recommendations for IP Stakeholders

  • Patent Search Best Practices: Always cross-reference EPO registers for full EP counts beyond case files.
  • Validity Challenges: Leverage EP 226 as prior art in pharma disputes.
  • SPC Planning: Model after EP 378 for drug extensions.
  • Global Filings: Align with counterparts like CA 176.

For comprehensive audits, consult databases; within these docs, stick to two EPs.

Key Takeaways

This analysis equips you with foundational insights into these EPs. For tailored advice, engage IP counsel. Explore more on patent law to safeguard innovations effectively.

#EuropeanPatents, #PatentLaw, #IPInsights
Chat Download
Chat Print
Chat R ALL
Landmark
Strategy
Argument
Risk
Chat Voice Bottom Icon
Chat Sent Bottom Icon
SupremeToday Portrait Ad
logo-black

An indispensable Tool for Legal Professionals, Endorsed by Various High Court and Judicial Officers

Please visit our Training & Support
Center or Contact Us for assistance

qr

Scan Me!

India’s Legal research and Law Firm App, Download now!

For Daily Legal Updates, Join us on :

whatsapp-icon telegram-icon
whatsapp-icon Back to top